Dr Kevin Maringer

Dr. Maringer is a molecular virologist studying dengue virus and other emerging flaviviruses. Research in his group is focussed on understanding how molecular virus-host interactions in humans and vectors could be exploited for developing new ways to treat dengue or prevent disease transmission. Molecular research in the group is complemented by field work in collaboration with a growing network of international partners in dengue-endemic countries (primarily Indonesia), with whom Dr. Maringer has also co-organised training and capacity-building workshops. Dr. Maringer has a keen interest in science policy and is passionate about actively improving diversity and inclusion in science. Dr. Maringer completed his PhD in herpesvirus biology at Imperial College London in 2011 and then began working on dengue as a Sir Henry Wellcome postdoctoral fellow at the Icahn School of Medicine at Mount Sinai in New York and at the University of Bristol. He set up his own research group at the University of Surrey in 2016, , and moved to The Pirbright Institute to take up a group leader position in 2020.